摘要
硼替佐米(bortezomib)是首个进入临床的蛋白酶体靶向药物,作为一线用药治疗多发性骨髓瘤和套细胞淋巴瘤时具有显著疗效,近年来针对硼替佐米相关机制的不断深入研究,使得硼替佐米可作为治疗急性白血病的潜在药物。前瞻性的研究表明,硼替佐米在与其他药物联用时能取得积极疗效,临床应用主要聚焦于初诊、复发难治急性髓系白血病与急性淋巴细胞白血病中的治疗,该文就硼替佐米在急性白血病中的应用研究进行综述。
Bortezomib is the first protease-targeted drug approved by the FDA,and it has significant effects in the treatment of multiple myeloma and mantle cell lymphoma.The relevant mechanism for bortezomib may become a potential treatment for acute leukemia in recent years.There is evidence that bortezomib can benefit patients when used in combination with other therapies.Clinical applications are primarily focused on the treatment of newly dignosed and relapse/refractory acute myeloid leukemia as well as acute lymphoblastic leukemia.This findings summarize the basic mechanisms and current clinical development of bortezomib.
作者
徐盼
常林林
张世忠
主鸿鹄
XU Pan;CHANG Linlin;ZHANG Shizhong;ZHU Honghu(Medical College of China Three Gorges University,Yichang 443000,China;Third-Grade Pharmacological Laboratory on Traditional Chinese Medicine,China Three Gorges University,Yichang 443000,China;The Department of Hematology,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China)
出处
《中国细胞生物学学报》
CAS
CSCD
2023年第5期819-828,共10页
Chinese Journal of Cell Biology
基金
浙江省科技厅项目(批准号:2022C03005)资助的课题。
